Esperion Therapeutics, Inc. (NASDAQ: ESPR) 8.9% HIGHER; provided an update today from the ETC-1002 (bempedoic acid) End-of-Phase 2 meeting with ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE